Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria~* Measurable targets according to the mRECIST v1.1 criterion~* Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)~* Tumour not subject to interventive care (liver transplant, surgical resection or percutaneous destruction)~* BCLC A/B without portal or extra-hepatic invasion~* No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with or without chemotherapy)~* Age ≥ 18 years~* WHO 0 or 1~* Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L, PT ≥ 50%~* No heart failure (isotope or ultrasound VEF \> 50%)~Exclusion Criteria:~* - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or diffuse HCC with liver invasion \> 50%)~* History of other type of cancer except cancer known to be in remission for more than 5 years (in this case, HCC histological proof is required), or basal-cell carcinoma or in situ cervix uteri cancer properly treated with curative treatment~* Advanced liver disease (Child B8, B9 and C, bilirubinaemia \> 3 mg/dL, SGOT and SGPT \> 5 x ULN or 250 U/L)~* Previous treatment by idarubicin and/or doxorubicin~* Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or liver failure, yellow fever vaccine)~* Concurrent disease or uncontrolled severe clinical condition~* Uncontrolled severe infection~* Patient requiring long-term anticoagulant treatment~* Thrombosis of the portal vein or a 3-segment region or more~* Hepatofugal portal venous flow~* Presence of serious atheromatosis~* Presence of collateral vascular ways potentially affecting the normal regions during embolisation~* Presence of arthritis of the hepatic artery branches to be treated~* Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by coils~* Pregnancy or breastfeeding~* Absence of effective contraception (for men and women of childbearing age)~* Patient who cannot be regularly monitored on account of psychological, social, family- or geography-related reasons~* Concomitant participation of a patient in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DC-BEADS + Idarubicin (Type: EXPERIMENTAL): Chemoembolization with DC BEAD loaded with idarubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).